CEL-SCI Corporation
(NYSE Amex Equities : CVM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
-0.30%357.041.2%$818.74m
AMGNAmgen Inc.
-0.98%189.881.2%$543.49m
CELGCelgene Corporation
-0.31%85.081.2%$517.86m
GILDGilead Sciences, Inc.
-0.03%77.030.9%$473.33m
VRTXVertex Pharmaceuticals Incorporated
-1.14%178.061.9%$311.94m
REGNRegeneron Pharmaceuticals, Inc.
-0.42%366.192.6%$283.24m
ILMNIllumina, Inc.
0.44%310.463.5%$265.60m
SRPTSarepta Therapeutics, Inc.
-0.39%135.0116.6%$231.23m
BLUEBluebird Bio, Inc.
1.06%180.8515.7%$204.08m
ALXNAlexion Pharmaceuticals, Inc.
0.05%135.162.0%$176.64m
NKTRNektar Therapeutics
-1.30%48.445.6%$171.79m
EXASExact Sciences Corporation
0.58%68.0025.4%$159.68m
EXELExelixis, Inc.
-0.47%21.246.4%$135.76m
BMRNBioMarin Pharmaceutical Inc.
-0.90%101.944.4%$124.01m
AAgilent Technologies, Inc.
0.14%64.241.5%$122.79m

Company Profile

CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus or human papillomavirus co-infected patients. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.